New routes and formulations for allergen-specific immunotherapy

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 52, Issue 6, 1997, Pages 602-612

  Wheeler, A W ^a   Drachenberg, K J ^b  

^a Rosier Commercial Centre   (United Kingdom)

^b SmithKline Beecham Pharma   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; VACCINE;

ALLERGY; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN SPECIFICITY; DELAYED HYPERSENSITIVITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HUMAN; IMMUNOTHERAPY; MAST CELL; PRIORITY JOURNAL; REVIEW; VACCINATION;

EID: 0030752954     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1398-9995.1997.tb01038.x     Document Type: Review

References (72)

1. Curtis H. The immunizing cure for hay fever. N Y Med J 1900;74:16.
2. Noon L. Prophylactic inoculation against hay fever. Lancet 1911:1:1572-3.
3. Lowell FC, Franklin B. A double-blind study of the effectiveness and specificity of injection therapy in ragweed hay fever. N Engl J Med 1975;273:675-9.
4. Norman PS, Winkenwerder WL, Lichtenstein LM. Trials of alum-precipitated pollen extracts in the treatment of hay fever. J Allergy Clin Immunol 1972;50:31-44.
5. Ziegler RS, Schatz M. Immunotherapy of atopic disorders. Present state of the art and future perspectives. Pediatr Clin North Am 1981;65:987-1012.
6. CSM update: desensitising vaccines. BMJ 1986;293:948.
7. Lichtenstein LM, Norman PS, Winkenwerder WL. In vitro studies of human ragweed allergy: changes in cellular and humoral activity associated with specific desensitization. J Clin Invest 1966;45:1126-36.
8. Ishizaka K, Ishizaka T. Identification of E-antibodies as a carrier of reaginic activity. J Immunol 1967;99:1187-98.
9. Johansson SGO, Bennich HI, Wide L. A new class of immunoglobulin in human serum. Immunology 1968; 14:265.
10. Moran DM, Wheeler AW. Specific hyposensitisation. In: Buckle DR, Smith H, editors. Development of anti-asthma drugs. London: Butterworths, 1977:349-89.
11. Prausnitz ZC, Küstner H. Studien über Unberempfindlichkeit. Centralblatt Bacteriol 1921;86:160.
12. Romagnani S. Human Th1 and Th2 subsets: doubt no more. Immunol Today 1991;12:256-7.
13. Cook RA, Barnard JH, Hebald S, Stull A. Serological evidence of immunity with co-existing sensitisation in a type of human allergy (hay fever). J Exp Med 1935;62: 733-50.
14. Platts-Mills TAE. Local production of IgG, IgA and IgE antibodies in grass pollen hay fever. J Immunol 1979;122:2218-25.
15. Lessoff MH, Sobotka AK, Lichtenstein LM. Johns Hosp Med J 1978;142:1.
16. Reisman RE. Insect allergy. In: Gupta S, Good RA, editors. Comprehensive immunology: cellular, molecular and clincal aspects of allergic disorders. New York: Plenum, 1979;6:381-95.
17. Foucard T, Johansson SGO. Allergen-specific IgE and IgG antibodies in pollen allergic children given immunotherapy for 2 to 6 years. Clin Allergy 1978;8:249-59.
18. Irons JS, Pruzansky JJ, Patterson R, Zeiss CR. Studies of perennial ragweed immunotherapy, associated changes in cellular responsiveness, total serum antigen-binding capacity and specific IgE antibody concentrations. J Allergy Clin Immunol 1977;59:190-9.
19. Pruzansky JJ, Golbert TM, Patterson R. Specific alterations in sensitivity of leukocytes of treated allergic patients. J Allergy 1968;Feb:114(Abstract 60).
20. Swineford O Jr. Non-specific passive desensitisation: a brief review. Ann Allergy 1972;30:464-72.
21. Bonifazi F, Antonicelli L, Bilò MB, et al. Hyposensitisation therapy of Parietaria-sensitive patients with a tyrosine adsorbed allergoid, Pollinex Parietaria (Bencard Parietaria). J Invest Allergol Clin Immunol 1991;1:37-44.
22. Rocklin RE, Sheffer AL. Generation of antigen-specific suppressor cells during allergy desensitisation. N Engl J Med 1980;302:1213-19.
23. Wheeler AW, Deards MJ, Hickman BE, Spackman VM, Johansson SGO. Reactivity of mast cell bound idiotypes with antiidiotypic antibodies. Mediator release or inhibition of antigen-induced mediator release? Int Arch Allergy Appl Immunol 1990:91;192-7.
24. St Remy J-MR. Novel approaches in immunotherapy. Clin Rev Allergy 1994;12:23-42.
25. van Bever HF, Stevens WJ. Suppression of the late asthmatic reaction by hyposensitisation in asthmatic children allergic to house dust mite (Dermatophagoides pteronyssinus). Clin Exp Allergy 1989;19:399-404.
26. Furin MJ, Norman PS, Creticos PS, et al. Immunotherapy decreases antigen-induced eosinophil migration into the nasal cavity. J Allergy Clin Immunol 1991;88:27-32.
27. Bousquet J, Michel FB. Advances in specific immunotherapy. Clin Exp Allergy 1992;22:889-96.
28. Mohapatra SS. Modulation of allergen-specific antibody responses by T-cell peptide vaccines(s). Clin Rev Allergy 1994;12:3-21.
29. Romagnani S. Induction of Th1 and Th2 responses: a key role for the "natural" immune response. Immunol Today 1992;13:379-81.
30. Mossman TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348-57.
31. Romagnani S, Del Prete OF, Maggi E, Ricci M. Th1 and Th2 cells and their role in disease. Res Trends 1993;5:19-22.
32. Hellman L, Carlsson M. Allergy vaccines. A review of developments. Clin Immunother 1996;6:130-42.
33. Sanderson CJ, Campbell HD, Young IG. Molecular and cellular biology of eosinophil differentiation factor (interleukin 5) and its effects on human and mouse B cells. Immunol Rev 1988;102:29.
34. Durham SR, Varney V, Gaga M, Frew AJ, Jacobson M, Kay AB. Immunotherapy and allergic inflammation. Clin Exp Allergy 1991;21:206-10.
35. εR2/CD23 expression on peripheral B cells correlates with successful hyposensitisation in grass pollinosis. J Allergy Clin Immunol 1995;95:77-87.
36. Schou C. Allergens in rhinitis. B- and T-cell epitopes of allergen molecules. Clin Exp Allergy 1995;25:10-14.
37. Harding F, McArthur J, Gross J, Raulet D, Allison J. Nature 1992;356:607-9.
38. Gramner LC, Shaughnessy MA, Suszko IM, Shaughnessy JJ, Patterson R. Persistence of efficacy after a brief course of polymerised ragweed allergen. A controlled study. J Allergy Clin Immunol 1984;73:484-9.
39. Mailing H-J, Weeke B. Immunotherapy. EAACI position paper. Allergy 1993;48 Suppl 14:9-35.
40. Sledge RF. Treatment of hay-fever with alum-precipitated pollen extract. U S Naval Bull 1938;36:18-29.
41. Whittall N, Moran DM, Wheeler AW, Cottam GP. Suppression of murine IgE responses with poly-(n-methylglycine)/ grass pollen extract conjugates using 4-(methylmercapto) phenyl-succinimidyl succinate as coupling reagent. Int Arch Allergy Appl Immunol 1985;76:354-60.
42. Wheeler AW, Moran DM, Robins BE, Driscoll A. L-Tyrosine as an immunological adjuvant. Int Arch Allergy Appl Immunol 1982;69:113-19.
43. Walls AF. Liposomes for allergy immunotherapy. Clin Exp Allergy 1992;22:1-2.
44. O'Hagan DT, Rahman D, Jeffery H, Sharif S, Challacombe SJ. Controlled release microparticles for oral immunisation. Int J Pharm 1994;108:133-9.
45. Carter EB. US patent 2019808: 1936.
46. Marsh DG, Lichtenstein LM, Campbell DH. Studies on "Allergoids" prepared from naturally occurring allergens. I. Assay of allergenicity and antigenicity of formalinized rye group 1 component. Immunology 1970;18:705-22.
47. Overell BGO, Spackman DA, Wheeler AW, Pfeiffer P. Standardisierung von Glutaraldehydemodifizierten Tyrosinadsorbieten Allergenextrakten. Allergologie 1991;14: 110-15.
48. Moran DM, Wheeler AW. Chemical modification of crude timothy grass pollen extract. I. Antigenicity and immunogenicity changes following amino group modification. Int Arch Allergy Appl Immunol 1976;50:693-708.
49. Bacal EB, Zeiss CR, Susco I, Levitz D, Patterson R. Polymerized whole ragweed: an improved method of immunotherapy. J Allergy Clin Immunol 1978;62:289-94.
50. Yang X, Gieni RS, Mossman TR. Chemically modified antigen preferentially elicits induction of Thl-Iike cytokine synthesis patterns in vivo. J Exp Med 1993;178:349-53.
51. Hayglas KT, Stefura BP. Antigen-specific inhibition of ongoing murine IgE responses. II. Inhibition of IgE responses by treatment with glutaraldehyde-modified allergens is paralleled by reciprocal increases in IgG2a synthesis. J Immunol 1991;147:2455-60.
52. Wie SI, Wie CH, Lee WY, Filion LG, Sehon AH, Akerblom E. Suppression of reaginic antibodies with modified allergens. III. Preparation of tolerogenic conjugates of common allergens with monomethoxy polyethylene glycols of different molecular weights by the mixed anhydride method. Int Arch Allergy Appl Immunol 1981;64:84-9.
53. Wheeler AW, Henderson DC, Carman AJ, Moran DM. Suppression of murine IgE responses with amino acid polymer/allergen conjugates. II. Suppressive activities in adjuvant-induced IgE responses. Int Arch Allergy Appl Immunol 1985;76:361-8.
54. Juniper EF, Roberts RS, Kennedy LK, O'Conner J, Syty-Golda M, Dolovitch J. Polyethylene glycol-modified ragweed pollen extract in rhinoconjunctivitis. J Allergy Clin Immunol 1985;75:578-85.
55. Notes for guidance on allergen extracts. European Agency for Evaluation of Medicinal Products. Revised Version, 1996.
56. Wheeler AW, Taylor H, Mehta V, Mitchell J, Reece D, Drachenberg K-J. Tyrosin-Allergoid Baumpollen. Stadardisierung mittels relevanter Methoden. Allergol J 1993;2: 71-5.
57. Allergen products for review. A technical guide. Paul Ehrlich Institute, 1992.
58. European Pharmacopeia. Allergen products. Producta allergenica. Jan 1997.
59. D'Amato G, Lobefalo G, Liccardi G, Cazzola G, Cazzola M. A double blind, placebo-controlled trial of local nasal immunotherapy in allergic rhinitis to Parietaria pollen. Clin Exp Allergy 1995;25:141-8.
60. Wortmann F. Oral hyposensitisation of children with pollinosis or house-dust asthma. Allergol Immunopathol (Madr) 1977;5:15-26.
61. Horak F, Wheeler AW. Oral hyposensitisation with entericcoated allergens as extension therapy following a basic subcutaneous course of injections. Int Arch Allergy Appl Immunol 1987;84:74-8.
62. Taudorf E, Laurssen LC, Björkstén B, et al. Oral hyposensitisation using birch pollen. Abstract 135, XII International Congress Allergology and Clinical Immunology Washington, DC, 1985.
63. Sharif S, Wheeler AW, O'Hagan DT. Biodegradable microparticles as a delivery system for the allergens of Dermatophagoides pteronyssinus (house dust mite). I. Preparation and characterisation of microparticles. Int J Pharm 1995; 119:239-46.
64. Scadding GK, Brostoft J. Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. Clin Allergy 1986;16:483-91.
65. van Nierkirk CH, De Wet JI. Efficacy of grass-maize pollen oral immunotherapy in patients with seasonal hay fever. A double-blind study. Clin Allergy 1987;17: 507-13.
66. Sabbah A, Hassoun S, Le Sellin J, André C, Sicard H. A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy 1994;49:309-13.
67. Wheeler AW, Sharif S. Sublingual delivery of vaccines: can we enhance the immune response induced by this route? Eur J Pharm Sci 1996;4 Suppl:539.
68. Valenta R, Vrtala S, Ball T, Laffer S, Steinberger P, Kraft D. Allergen-specific therapy in type I allergy: new concepts based on recombinant allergens. Allergy Clin Immunol News 1994;6:165-9.
69. Vrtala S, Grote M, Ferreira F, et al. Humoral immune responses to recombinant tree pollen allergens (Bet v 1, Bet v 2) in mice; construction of an oral allergy live vaccine. Int Arch Allergy Appl Immunol.
70. Norman PS, Ohman JL, Long AA. Early clinical experience with T-cell reactive peptides from cat allergen Fei d 1 [Abstract]. J Allergy Clin Immunol 1993;93:231.
71. Norman PS, Ohman JL, Long AA. Follow on study of the first clinical trial with T cell defined peptides from cat allergen Fel d 1 [Abstract]. J Allergy Clin Immunol 1995; 95:259.
72. O'Hehir RE, Hoyne GF, Thomas WR. House dust mite allergy from T cell epitopes to immunotherapy. Eur J Clin Invest 1993;23:763-72.